Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Investor Day (September 2008)
11 slides from Teva Pharmaceutical Industries's investor day presentation, Sep 8, 2008
Slide 1: Teva Innovative Ventures: Investments
Teva Innovative Ventures: Investments Aharon Schwartz, PhD, VP, Teva Innovative Ventures September 8, 2008 Tel Aviv
Slide 2: TIV's Strategy to Expand Teva's Pipeline
TIV’s Strategy to Expand Teva’s Pipeline Development only Broad (“niche”) TAs Integrate In-licensing (no “competitive” internal research) (priority to MS, Neurology, AI, Oncology) and Investments Key Success Factors More “Shots on Goal” Be Efficient & Effective Global sourcing Evaluation Increase in
Slide 3: TIV Investments: Additional Avenue to Expand Teva's Pipeline
TIV Investments: Additional Avenue to Expand Teva’s Pipeline ! " ! ! " Teva provides much needed resources to the portfolio companies through Teva’s IR&D: Analytical & preclinical expertise Clinical studies Regulatory affairs This enables smooth transition into Teva’s pipeline once a strategic optio
Slide 4: Through TIV Investments, Teva Expands into New Technologies
Through TIV Investments, Teva Expands into New Technologies Oncology mABs Wound Care Diabetes
Slide 5: Teva Has Equity in 20 Start-up Companies
Teva Has Equity in 20 Start-up Companies Teva has strategic rights in many of the investments +& # * & # * ( !$ *& * & $ % & ' ,) '() *(! -
Slide 6: BMI: Teva's First Investment in an Investment Company
BMI: Teva’s First Investment in an Investment Company ( $ ! BMI was formed in 1997; Teva ( holds 33% equity Invested in 10 companies 3 still in portfolio 3 exits + 1 partial exit !! 4 closed * * .
Slide 7: Teva Acquired Strategic Rights in 2 BMI Companies
Teva Acquired Strategic Rights in 2 BMI Companies ( $ ! ( !! /) * /- ' & * .
Slide 8: CBI: Teva's More Recent Indirect Investment
CBI: Teva’s More Recent Indirect Investment * ( 0$ * " CBI was formed in 1999; Teva invested $ in CBI and holds ~13% equity Invested in 16 companies 12 still in portfolio ! 4 partial exits 3 closed/written-off $ % & " ! Went public on TASE Substantial cash and commitments for *& additional investmen
Slide 9: Teva Acquired Strategic Rights in 4 CBI Companies
Teva Acquired Strategic Rights in 4 CBI Companies * ( 0$ * " $ ! /) $ % & " ! /) *& / "# (& & /)
Slide 10: Investing has its Advantages: Estimated Launch Dates/Financials
Investing has its Advantages: Estimated Launch Dates/Financials 1225 1223 1242 1244 1241 1246 1247 1248 DiaPep277 DebraseTM StemExTM CT-011 (Type 1 (Burns) (Cancer) (Cancer ) Diabetes) Teva Funding of Projects through Regulatory Approval (RA) % Invested To Date 10% Additional Investments through RA
Slide 11: Thank You!
Thank You! 11 wit TEVA PHARMACEUTICAL INDUSTRIES LTD.
Teva Pharmaceutical Industries — Investor Day (September 2008) on 6ix